XTL Biopharmaceuticals
Herzliya
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2017)
- Ticker: nasdaq:XTLB
- Website: xtlbio.com
- Phone: +972 9-955-7080
Industries & Categories
Biotechnology, Developer Platform, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/xtl-biopharmaceuticals-24905 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.